ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · IEX Real-Time Price · USD
1.810
+0.010 (0.56%)
Jul 19, 2024, 11:59 AM EDT - Market open

Company Description

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.

The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.

In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.

The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V.
ProQR Therapeutics logo
Country Netherlands
Founded 2012
IPO Date Sep 18, 2014
Industry Biotechnology
Sector Healthcare
Employees 157
CEO Daniel Anton de Boer

Contact Details

Address:
Zernikedreef 9
Leiden, P7 2333 CK
Netherlands
Phone 31 88 166 7000
Website proqr.com

Stock Details

Ticker Symbol PRQR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
CIK Code 0001612940
CUSIP Number N71542109
ISIN Number NL0010872495
SIC Code 2834

Key Executives

Name Position
Daniel Anton de Boer Founder, Chief Executive Officer and Member of Management Board
Dr. Domenico Valerio Ph.D. Founder and Independent Chairman of Supervisory Board
Rene K. Beukema Chief Corporate Development Officer, General Counsel and Member of Management Board
Dr. Gerard Platenburg Co-Founder and Chief Scientific Officer
Jurriaan Dekkers Chief Financial Officer
Sheila Sponselee Chief People and Operations Officer
Sarah Cue Kiely Vice President of Investor Relations and Corporate Communications
Sandra van der Kolk Junior Financial Controller

Latest SEC Filings

Date Type Title
May 22, 2024 6-K Report of foreign issuer
May 9, 2024 6-K Report of foreign issuer
May 8, 2024 6-K Report of foreign issuer
Apr 23, 2024 6-K Report of foreign issuer
Apr 19, 2024 6-K Report of foreign issuer
Mar 13, 2024 20-F Annual and transition report of foreign private issuers
Mar 13, 2024 6-K Report of foreign issuer
Feb 15, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals